GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Deferred Tax

BLIS Technologies (NZSE:BLT) Deferred Tax : NZ$0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

BLIS Technologies's change in deferred tax for the six months ended in Mar. 2024 was NZ$0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$0.00 Mil.


BLIS Technologies Deferred Tax Historical Data

The historical data trend for BLIS Technologies's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Deferred Tax Chart

BLIS Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BLIS Technologies Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BLIS Technologies Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BLIS Technologies Deferred Tax Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016